Vanguard Group Inc Alnylam Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,297,139 shares of ALNY stock, worth $5.72 Billion. This represents 0.07% of its overall portfolio holdings.
Number of Shares
13,297,139
Previous 13,056,605
1.84%
Holding current value
$5.72 Billion
Previous $3.53 Billion
22.99%
% of portfolio
0.07%
Previous 0.07%
Shares
17 transactions
Others Institutions Holding ALNY
# of Institutions
745Shares Held
111MCall Options Held
916KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.7MShares$7.2 Billion0.76% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.1 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$3.08 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.9 Billion0.79% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.51MShares$1.51 Billion0.12% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $52.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...